D
David Herrmann
Researcher at Garvan Institute of Medical Research
Publications - 42
Citations - 2124
David Herrmann is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 20, co-authored 36 publications receiving 1404 citations. Previous affiliations of David Herrmann include University of New South Wales & University of Freiburg.
Papers
More filters
Journal ArticleDOI
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
Aurélie Cazet,Aurélie Cazet,Mun N. Hui,Benjamin Elsworth,Sunny Z. Wu,Sunny Z. Wu,Daniel L. Roden,Daniel L. Roden,Chia Ling Chan,Joanna N. Skhinas,Raphael Collot,Jessica Yang,Kate Harvey,M. Zahied Johan,M. Zahied Johan,Caroline Cooper,Radhika Nair,David Herrmann,David Herrmann,Andrea McFarland,Niantao Deng,Niantao Deng,Manuel Ruiz-Borrego,Federico Rojo,Jose Manuel Trigo,Susana Bezares,Rosalía Caballero,Elgene Lim,Paul Timpson,Paul Timpson,Sandra A O'Toole,Sandra A O'Toole,D. Neil Watkins,Thomas R. Cox,Thomas R. Cox,Michael S. Samuel,Michael S. Samuel,Miguel Martin,Alexander Swarbrick,Alexander Swarbrick +39 more
TL;DR: It is demonstrated that cancer cell-derived Hedgehog ligand triggers stromal remodeling that in turn induces a cancer-stem-cell like, drug-resistant phenotype of nearby cancer cells while treatment with smoothened inhibitors reverses these phenotypes.
Journal ArticleDOI
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
Claire Vennin,Claire Vennin,Venessa T. Chin,Venessa T. Chin,Sean C. Warren,Sean C. Warren,Morghan C. Lucas,Morghan C. Lucas,David Herrmann,David Herrmann,Astrid Magenau,Astrid Magenau,Pauline Mélénec,Pauline Mélénec,Stacey N. Walters,Stacey N. Walters,Gonzalo del Monte-Nieto,Gonzalo del Monte-Nieto,James R.W. Conway,James R.W. Conway,Max Nobis,Max Nobis,Amr H. Allam,Amr H. Allam,Rachael A. McCloy,Rachael A. McCloy,Nicola Currey,Nicola Currey,Mark Pinese,Mark Pinese,Alice Boulghourjian,Anaiis Zaratzian,Arne A. S. Adam,Celine Heu,Adnan Nagrial,Angela Chou,Angela Chou,Angela Chou,Angela Steinmann,Alison Drury,Danielle Froio,Marc Giry-Laterriere,Marc Giry-Laterriere,Nathanial L. E. Harris,Nathanial L. E. Harris,Tri Giang Phan,Tri Giang Phan,Rohit Jain,Wolfgang Weninger,Wolfgang Weninger,Ewan J. McGhee,Renee Whan,Amber L. Johns,Jaswinder S. Samra,Lorraine A. Chantrill,Lorraine A. Chantrill,Anthony J. Gill,Maija R.J. Kohonen-Corish,Maija R.J. Kohonen-Corish,Maija R.J. Kohonen-Corish,Richard P. Harvey,Richard P. Harvey,Andrew V. Biankin,Andrew V. Biankin,T.R. Jeffry Evans,Kurt I. Anderson,Shane T. Grey,Shane T. Grey,Christopher J. Ormandy,Christopher J. Ormandy,David Gallego-Ortega,David Gallego-Ortega,Yingxiao Wang,Michael S. Samuel,Owen J. Sansom,Andrew Burgess,Andrew Burgess,Thomas R. Cox,Thomas R. Cox,Jennifer P. Morton,Marina Pajic,Marina Pajic,Paul Timpson,Paul Timpson +83 more
TL;DR: A graded response to priming is demonstrated in stratified patient-derived tumors, indicating that fine-tuned tissue manipulation before chemotherapy may offer opportunities in both primary and metastatic targeting of pancreatic cancer.
Journal ArticleDOI
Fluids and their mechanics in tumour transit: shaping metastasis
Gautier Follain,Gautier Follain,David Herrmann,David Herrmann,Sébastien Harlepp,Sébastien Harlepp,Vincent Hyenne,Naël Osmani,Naël Osmani,Sean C. Warren,Sean C. Warren,Paul Timpson,Paul Timpson,Jacky G. Goetz,Jacky G. Goetz +14 more
TL;DR: The role of bodily fluids and their underlying forces and imposed stresses in metastasis is discussed, highlighting the contributions of fluid mechanics to tumour cell intravasation, intravascular arrest and extravasation as well as to dissemination of tumour-derived factors.
Journal ArticleDOI
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer.
Brooke A. Pereira,Claire Vennin,Michael Papanicolaou,Cecilia R. Chambers,Cecilia R. Chambers,David Herrmann,David Herrmann,Jennifer P. Morton,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson +11 more
TL;DR: This review explores how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC).
Journal ArticleDOI
CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan
Claire Vennin,Claire Vennin,Claire Vennin,Pauline Mélénec,Pauline Mélénec,Romain Rouet,Romain Rouet,Max Nobis,Max Nobis,Aurélie Cazet,Aurélie Cazet,Kendelle J. Murphy,Kendelle J. Murphy,David Herrmann,David Herrmann,Daniel A Reed,Daniel A Reed,Morghan C. Lucas,Morghan C. Lucas,Sean C. Warren,Sean C. Warren,Zehra Elgundi,Mark Pinese,Mark Pinese,Gabriella Kalna,Daniel L. Roden,Daniel L. Roden,Monisha Samuel,Anaiis Zaratzian,Shane T. Grey,Shane T. Grey,Andrew M. Da Silva,Wilfred Leung,Wilfred Leung,Wilfred Leung,Australian Pancreatic Genome Initiative,Suresh Mathivanan,Yingxiao Wang,Anthony W Braithwaite,Anthony W Braithwaite,Daniel Christ,Daniel Christ,Aleš Benda,Ashleigh Parkin,Ashleigh Parkin,Phoebe A. Phillips,John M. Whitelock,Anthony J. Gill,Owen J. Sansom,David R. Croucher,David R. Croucher,Benjamin L. Parker,Marina Pajic,Marina Pajic,Jennifer P. Morton,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson +58 more
TL;DR: It is revealed that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer and identifying perle can as a mediator of the pro-metastatic environment.